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Volume 60, Number 4 Abstracts 1095thrombolytic therapy. Only about 3.4 to 5% of patients with acute PE are
unstable so randomized data on use of vena cava ﬁlters in patients with un-
stable PE seems unlikely to happen any time soon. What this data does sug-
gest is that old age at least should not be considered a limiting factor when
considering a vena cava ﬁlter in unstable PE patients. The paper does not
deﬁnitively prove that the ﬁlters are required, but it does suggest that
they do not hurt at least in the short term.
Serious Bleeding Events due to Warfarin and Antibiotic
Co-Prescription in a Cohort of Veterans
Lane MA, Zeringue A, McDonald JR. Am J Med 2014;127:657-63.
Conclusions: Patients on Warfarin who are prescribed certain ‘high-
risk’ antibiotics are at higher risk for serious bleeding events.
Summary: Warfarin has a well-known narrow therapeutic index
requiring frequent laboratory monitoring to prevent life-threatening com-
plications due to under- and over-anticoagulation. There are a wide variety
of factors including genetics, dietary factors, and drug interactions as well as
comorbidities that produce signiﬁcant variability in an individual’s dose
response to waraﬁn. Medications that alter the metabolism of warfarin
by inducing or inhibiting cytochrome P450-2C9, may result in a decrease
or increase in anticoagulant effect. Antibiotics such as trimethoprim/sul-
famethoxazole, metronidazole, ﬂuconazole, ciproﬂoxacin, levoﬂoxacin,
azithromycin, and clarithromycin interact with warfarin via the cyto-
chrome P450-2C9 pathway and also may eliminate vitamin K-producing
bacteria in the intestines to further alter the therapeutic effect of warfarin.
Given these antibiotic interactions with warfarin, the authors performed a
retrospective cohort study of veterans who were prescribed warfarin for
30 days without interruption through the U.S. Department of Veterans
Affairs between October 1, 2002 and September 1, 2008. Antibiotics
considered to be high risk for interaction with warfarin (noted above) as
well as ‘low-risk’ antibiotics such as clindamycin and cephalexin were
tracked in these patients. Risk of bleeding event within 30 days of antibi-
otic exposure was measured using Cox proportional hazards regression,
adjusted for demographic characteristics, comorbid conditions, and
receipt of other medications interacting with warfarin. There were a total
of 22,272 patients who met inclusion criteria, with 14,078 and 8194
receiving high- and low-risk antibiotics respectively. There were 93 and
36 bleeding events in the high- and low-risk groups respectively. Receipt
of a ‘high-risk’ antibiotic (hazard ratio [HR], 1.48; 95% CI, 1.00-2.19)
and azithromycin (HR, 1.93; 95% CI, 1.13-3.30) were associated with
increased risk of bleeding as a primary diagnosis. Other ‘high-risk’ antibi-
otics including ciproﬂoxacin, levoﬂoxacin, azithromycin, and trimetho-
prim/sulfamethoxazole were also associated with serious bleeding as a
primary or secondary diagnosis. International normalized ratio (INR) al-
terations were common; 9.7% of patients prescribed ﬂuconazole had
INR values >6. Patients who had an INR performed within 3-14 days
following antibiotic prescription were at decreased risk of serious bleeding
(HR, 0.61; 95% CI, 0.42-0.88).
Comment: The paper highlights known ‘high-risk’ antibiotics for
interaction with warfarin in that alterations in the INR values are common
among patients who receive such antibiotics. In addition, the fact that INR
evaluation within 3-14 days of antibiotic prescription appeared to reduce the
risk of serious bleeding events among patients receiving warfarin indicates
that monitoring INR shortly after beginning a course of the more ‘high-
risk’ antibiotics, should be routine.
Stroke Incidence and Mortality Trends in US Communities, 1987 to
2011
Koton S, Schneider ALC, Rosamond WD, et al. JAMA 2014;312:259-68.
Conclusions: Stroke incidence and stroke mortality rates have
decreased from 1987 to 2011. Decreases vary across age groups, but are
similar across race and sex, indicating improvements in stroke incidence
and outcome continued to 2011.
Summary: The Atherosclerosis Risk in Communities (ARIC) Study
is a prospective study of 15,792 residents in 4 US communities, who were
aged 45 to 64 years at baseline (1987-1989). The study was designed to
investigate variation in cardiovascular diseases by race, sex, location, and
date (Rosamond WD et al, Stroke 1999; 30:736-43). Information on car-
diovascular risk factors and self-reported race was collected at baseline
through interviews and physical examinations. Follow-up has been with
examinations (1990-1992, 1993-1995, and 1996-1998), annual phone
interviews, and active surveillance of discharges from local hospitals as
well as linkage with the National Death Index through December 31,
2011. In this paper the authors utilized patients from the ARIC cohort
from 1987 to 2011. There were 14,357 participants (282,097 person-years) free of stroke at baseline. Participants were recruited for the purpose
of studying all stroke hospitalizations and deaths, and for collection of
baseline information on cardiovascular risk factors (via interviews and
physical examinations) in 1987-1989. A physician reviewer adjudicated
all possible strokes and classiﬁed them as deﬁnite or probable ischemic
or hemorrhagic events. The main outcome measures for the study were
trends in rates of ﬁrst-ever stroke per 10 years of calendar time, estimated
using Poisson regression incidence rate ratios (IRRs), with subsequent
mortality analyzed using Cox proportional hazards regression models
and hazard ratios overall and by race, sex, and age divided at 65 years.
Among 1051 (7%) participants with incident stroke, there were 929 inci-
dent ischemic strokes and 140 with incident hemorrhagic strokes (18 par-
ticipants had both during the study period). Crude incidence rates were
3.73 (95% CI, 3.51-3.96) per 1000 person-years for ischemic stroke
and 0.49 (95% CI, 0.41-0.57) per 1000 person-years for hemorrhagic
stroke. Stoke incidence decreased over time in both white and black par-
ticipants (age-adjusted IRRs per 10-year period, 0.97; 95% CI, 0.76-1.25;
absolute decrease of 0.09 per 1000 person-years, P ¼ .02 for interaction).
The decrease in incidence was similar by sex of participants. Of patients
with incident stroke, 614 (58%) died through 2011. The mortality rate
was higher for hemorrhagic stroke (68%) than for ischemic stroke
(57%). Overall, mortality after stroke decreased over time from absolute
of 8.09 per 100 strokes after 10 years. The decrease in mortality was
mostly accounted for by the decrease in patients younger than 65 years
at the time of incident stroke (HR, 0.65; 95% CI, 0.46-0.93; absolute
decrease of 14.19 per 100 strokes after 10 years but was similar across
race and sex.
Comment: The data indicate the overall decline in stroke mortality is
a combination of decreases in stroke incidence and mortality from stroke
across age. It is encouraging that the decline in incidence is similar in white
and black participants as well as in men and women. However, on the not so
encouraging side, younger participants in the study had no change in their
stroke incidence. A bright spot for the younger patients was that although
stroke incidence was unchanged in the younger patients, stroke mortality
was decreased.
Effect of Supervised Exercise on Physical Function and Balance in
Patients With Intermittent Claudication
Mockford KA, Gohil RA, Mazari F, et al. BJS 2014;101:356-62.
Conclusions: Supervised exercise programs improve physical function
and balance impairment.
Summary: In patients with intermittent claudication exercise im-
proves walking distances, quality of life, and raises levels of daily activity
thereby reducing functional decline and associated morbidity and mortal-
ity in both mid and long tern (McDermott MM et al, J Am Coll Cardiol
2012;59:1159-67). There is also increasing evidence patients with claudi-
cation have balance impairment, suggesting that if exercise can improve
claudication parameters it may also serve as a mechanism of improving
balance and reducing risk of falls and their associated physical and socio-
economic consequences in patients with intermittent claudication. The
purpose of this study was to determine whether a standard supervised
exercise program (SEP) for patients with intermittent claudication
improved speciﬁc measures of functional performance that included
balance. This was a prospective observational study performed at a single
tertiary vascular center in the UK. Patients with intermittent claudication
(Rutherford grades 1-3) were included in the study. They were assessed
at baseline (before SEP) and at 3, 6, and 12 months afterwards for
markers of lower limb ischemia (treadmill walking distance and ankle
brachial index), physical function (6-min walk, Timed Up and Go test,
and Short Physical Performance Battery (SPPB) score), as well as balance
impairment using computerized dynamic posturography with the Sensory
Organization Test (SOT), and quality of life (VascuQoL and Short
Form 36). There were ﬁfty-one participants who underwent SEP. This
signiﬁcantly improved treadmill walking distance (P ¼ .001). Enrollment
in SEP also resulted in improvements in physical function as determined
by the 6-minute maximum walking distance (P ¼ .006), SPPB score
(P < .001), and some domains of both generic (bodily pain,
P ¼ .025) and disease-speciﬁc (social domain, P ¼ .039) quality of life.
There were also signiﬁcant improvements noted in balance, as deter-
mined by the SOT (P < .001).
Comment: The authors point out that a parallel study assessing
the role of percutaneous transluminal angioplasty for claudication showed
no effect on balance. The additional favorable effect of supervised exercise
on balance in addition to quality of life measures and walking distance
provides additional evidence supporting the position that exercise therapy
along with medical management should be the initial and primary interven-
tions in patients with intermittent claudication.
